Intravenous immunoglobulin therapy for COVID-19 ARDS

Lancet Respir Med. 2022 Feb;10(2):123-125. doi: 10.1016/S2213-2600(21)00450-1. Epub 2021 Nov 11.

Authors

Erin M Wilfong¹, Michael A Matthay²

Affiliations

¹ Division of Rheumatology and Immunology and Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: erin.m.wilfong@vumc.org.
² Department of Medicine and Department of Anesthesia, Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.

No abstract available

MeSH terms

COVID-19*
Humans
Immunoglobulins, Intravenous
Respiration, Artificial
Respiratory Distress Syndrome* / drug therapy
SARS-CoV-2

Substances

Immunoglobulins, Intravenous

Grants and funding

KL2 TR002245/TR/NCATS NIH HHS/United States